Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alpha Cognition Inc.
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
January 14, 2025
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOG
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
January 06, 2025
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOG
Alpha Cognition Announces Partial Exercise of Over-allotment Option
December 16, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOG
CSE:ACOG
Alpha Cognition Announces Voluntary Delisting from CSE
December 12, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOG
CSE:ACOG
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
December 11, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOG
CSE:ACOG
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
November 15, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOG
CSE:ACOG
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing
November 12, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOG
CSE:ACOG
Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting
October 31, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Appointment of VP Finance and Accounting
October 21, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
October 15, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Change of Officer
October 03, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
September 24, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
August 19, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
August 13, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
August 12, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOG
CSE:ACOG
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
July 29, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
February 22, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Provides Business Update
February 12, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
January 19, 2024
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
December 22, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
December 07, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
December 04, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
October 16, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
August 31, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Launches $6.5 Million Private Placement
May 30, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
CSE:ACOG
Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
March 08, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
TSX:ACOG
Alpha Cognition Provides Private Placement Update
March 06, 2023
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
TSX-V:ACOG
Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
November 28, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
TSX-V:ACOG
Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update
August 25, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
TSX-V:ACOG
Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease
August 22, 2022
From
Alpha Cognition Inc.
Via
Business Wire
Tickers
ACOGF
TSX-V:ACOG
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.